1 | Azithromycin | Azithromycin 14件: Azithromycin; Azithromycin (zitromax°); Azithromycin + metronidazole; Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin 250 mg tablets; Azithromycin 250mg capsule; Azithromycin 500 mg film-coated tablet; Azithromycin dihydrate; Azithromycin monohydrate; Azithromycine; Azithromycine 250 mg; Po azithromycin; Rifampin and azithromycin.; Study medication, azithromycin; | 3件: D02134 D02134
D06390 D06390
D07486 D07486 💬 |
- |
- |
013 6件: 13, 84, 85, 96, 228, 299 💬 |
2 | Aztreonam | Aztreonam 11件: Aztreonam; Aztreonam for inhalation (ai); Aztreonam for inhalation solution; Aztreonam for inhalation solution (azli); Aztreonam lysine; Aztreonam lysine for inhalation; Aztreonam lysine for inhalation (azli); Aztreonam solución para inhalación; Cayston aztreonam 75 mg powder and solvent for nebuliser solution; Nasal aztreonam; Oral aztreonam; | 2件: D00240 D00240
D06558 D06558 💬 |
- |
- |
228 2件: 228, 299 💬 |
3 | Basiliximab | Basiliximab 1件: Basiliximab; | 1件: D03058 D03058 💬 |
1件: IL2RA 💬 |
Cytokine-cytokine receptor interaction 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 7件: 2 , 50, 65, 66, 97, 222, 228 💬 |
4 | Bortezomib | Bortezomib 8件: Bortezomib; Bortezomib (velcade®); Bortezomib/dexamethasone; Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Combination of a single dose anti-cd20 antibody and bortezomib; Cyclophosphamide, bortezomib, and dexamethasone (cybord); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; | 1件: D03150 D03150 💬 |
1件: PSMB5 💬 |
Alzheimer disease 8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
011 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬 |
5 | Budesonide | 0.5 mg budesonide effervescent tablet for orodispersible use 49件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 6 mg prolonged-release capsule, hard (bux-pvii prototype); Budesonide 6 mg prolonged-release capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg prolonged-release capsule, hard (bux-pvii prototype); Budesonide 9 mg prolonged-release capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose budesonide; High dose budesonide suspension; High dose budesonide tablet; High dose of budesonide; Inhaled/swallowed budesonide; Low dose budesonide; Low dose budesonide tablet; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide; | 1件: D00246 D00246 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
066 9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬 |
6 | Chloride ion | - | - |
- |
- |
006 25件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
7 | Cholecalciferol | 5000 iu of cholecalciferol 11件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol (vitamind3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol concentrate (water-dispersible form); Cholecalciferol, vitamin d3; | 1件: D00188 D00188 💬 |
1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
006 23件: 6 , 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 162, 202, 228, 271, 298, 299 💬 |
8 | Clarithromycin | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine 8件: A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine; Biaxin ( clarithromycin); Clarithromycin; Clarithromycin (not used as of 4/2020); Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Rifabutin, clarithromycin, and clofazimine; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication); | 1件: D00276 D00276 💬 |
- |
- |
006 8件: 6 , 63, 84, 96, 97, 222, 228, 299 💬 |
9 | Cyclosporine | Atg+cyclosporine 26件: Atg+cyclosporine; Atg+rapamune+cyclosporine; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide,cyclosporine a; Cyclosporine; Cyclosporine (gengraf ); Cyclosporine (usan); Cyclosporine 5 mg/kg bid days 0-14; Cyclosporine a; Cyclosporine a (csa); Cyclosporine a dry powder inhalation (drug); Cyclosporine combine with mycophenolate mofetil; Cyclosporine inhalation solution; Cyclosporine inhalation solution (cis); Cyclosporine oral product; Cyclosporine pill; Cyclosporine vs infliximab; Cyclosporine-a; Device: cyclosporine a; Liposomal aerosol cyclosporine; Liposomal cyclosporine a; Liposomal cyclosporine a 10 mg; Liposomal cyclosporine a 5 mg; Oral cyclosporine; Rabbit atg, cyclosporine, levamisole; Twice-daily dosage with 0.5% cyclosporine-a eyedrops; | 1件: D00184 D00184 💬 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬 |
10 | Erythromycin | Erythromycin 3件: Erythromycin; Erythromycine; Oral erythromycin; | 9件: D00140 D00140
D00851 D00851
D01361 D01361
D02009 D02009
D02184 D02184
D02523 D02523
D02524 D02524
D02525 D02525
D04054 D04054 💬 |
- |
- |
006 5件: 6 , 36, 164, 228, 291 💬 |
11 | Etanercept | 50 mg etanercept 49件: 50 mg etanercept; Adalimuab, etanercept, tocilizumab, or abatacept; Adalimumab, etanercept, golimumab or infliximab; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Enbrel (etanercept); Etanercept; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (enbrel); Etanercept (enbreltm); Etanercept (etn); Etanercept (full-dose); Etanercept (half-dose); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50 mg sc day 0 and day 3; Etanercept 50 mg/ml; Etanercept 50mg; Etanercept auto-injector; Etanercept biosimilar; Etanercept liquid; Etanercept optimal dosing; Etanercept or adalimumab; Etanercept pre-filled syringe; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, methotrexate and depomedrone; Etanercept, methotrexate, prednisolone; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Lyophilized etanercept powder(yisaipu); Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Prefilled liquid etanercept(yisaipu); Procedure: intra-articular injection of etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tapering or discontinuation of etanercept; Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | 1件: D00742 D00742 💬 |
2件: LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
015 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 💬 |
12 | Everolimus | Afinitor (everolimus) 8件: Afinitor (everolimus); Everolimus; Everolimus (rad001); Everolimus (rad001) , afinitor®; Everolimus 2mg dispersible tablet; Everolimus oral product; Rad001, everolimus; Rad001: everolimus; | 1件: D02714 D02714 💬 |
1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
034 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬 |
13 | Fluticasone | Fluticasone 7件: Fluticasone; Fluticasone mdi; Fluticasone propionate; Fluticasone propionate, 800 mcg twice daily (post 4fed failure); Fluticasone propionate, 880 mcg twice daily (after 6fed failure); Fluticasone propionate, usp; Swallowed fluticasone; | 1件: D07981 D07981 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
098 3件: 98, 228, 299 💬 |
14 | Fluticasone propionate | Fluticasone propionate 4件: Fluticasone propionate; Fluticasone propionate, 800 mcg twice daily (post 4fed failure); Fluticasone propionate, 880 mcg twice daily (after 6fed failure); Fluticasone propionate, usp; | 1件: D01708 D01708 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
098 2件: 98, 228 💬 |
15 | Formoterol | Budesonide-formoterol single inhaler 5件: Budesonide-formoterol single inhaler; Budesonide/formoterol; Formoterol; Formoterol fumarate dihydrate; Formoterol/budesonide; | 3件: D01373 D01373
D05277 D05277
D07990 D07990 💬 |
1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
085 3件: 85, 228, 299 💬 |
16 | Helium | Helium 6件: Helium; Helium / oxygen mixed gas inhalation therapy; Helium-3; Hyperpolarized helium-3; Hyperpolarized helium-3 mri; Hyperpolarized helium-3 mri of the chest; | 1件: D04420 D04420 💬 |
- |
- |
228 3件: 228, 299, 330 💬 |
17 | Helium He-3 | - | - |
- |
- |
228 2件: 228, 299 💬 |
18 | Interferon Gamma | Fully human anti-interferon gamma monoclonal antibody 5件: Fully human anti-interferon gamma monoclonal antibody; Interferon gamma; Interferon gamma 1b; Interferon gamma-1b; Interferon gamma-1b (actimmune); | - |
- |
- |
018 8件: 18, 65, 85, 107, 228, 299, 301, 326 💬 |
19 | Interferon gamma-1b | Interferon gamma-1b 2件: Interferon gamma-1b; Interferon gamma-1b (actimmune); | 1件: D00747 D00747 💬 |
2件: IFNGR1, IFNGR2 💬 |
Chagas disease 18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
018 7件: 18, 65, 85, 228, 299, 301, 326 💬 |
20 | Iron (III) oxide adipate | - | - |
- |
- |
097 2件: 97, 228 💬 |
21 | Itacitinib | Itacitinib 2件: Itacitinib; Itacitinib adipate; | 1件: D10944 D10944 💬 |
1件: JAK1 💬 |
Coronavirus disease - COVID-19 27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 5件: 46, 51, 60, 97, 228 💬 |
22 | L-Lysine | L-lysine 6件: L-lysine; L-lysine n acetylcysteinate; L-lysine n-acetylcysteinate; L-lysine- n-acetylcysteinate; L-lysine-n-acetyl-l-cysteinate; L-lysine-n-acetylcysteinate; | 1件: D02304 D02304 💬 |
- |
- |
013 5件: 13, 19, 97, 228, 299 💬 |
23 | Lactose | 2'-fucosyllactose 4件: 2'-fucosyllactose; Lactose; Lactose in water; Lactose monohydrate; | 2件: D00046 D00046
D03226 D03226 💬 |
- |
- |
002 6件: 2 , 6 , 13, 97, 228, 310 💬 |
24 | Montelukast | 5 mg montelukast 8件: 5 mg montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast; Montelukast sodium; Montelukast teva; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Montelukast/ singulair; Singulair (montelukast sodium); | 2件: D00529 D00529
D08229 D08229 💬 |
1件: CYSLTR1 💬 |
Calcium signaling pathway 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
013 5件: 13, 46, 85, 98, 228 💬 |
25 | Mycophenolic acid | Mycophenolic acid 2件: Mycophenolic acid; Mycophenolic acid mofetil; | 1件: D05096 D05096 💬 |
2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 34件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
26 | Nintedanib | L01xe31 - nintedanib 5件: L01xe31 - nintedanib; Nintedanib; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Sub-study: nintedanib; | 1件: D10481 D10481 💬 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 |
Adherens junction 34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
051 5件: 51, 85, 89, 227, 228 💬 |
27 | Pirfenidone | Pirfenidone 7件: Pirfenidone; Pirfenidone (pfd); Pirfenidone 267 mg [esbriet]; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Pirfenidoneone; Sub-study: pirfenidone; | 1件: D01583 D01583 💬 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 82件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
034 10件: 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬 |
28 | Prednisone | 0 mg prednisone 73件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; Adalimumab, plus prednisone; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Enalapril valsartan methylprednisone; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Ir prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Methylprednisone; Mr prednisone; Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Other: prednisone; Over encapsulated prednisone; Prednisolone/prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 1 mg; Prednisone 15 mg; Prednisone 2 mg; Prednisone 3 mg; Prednisone 4 mg; Prednisone 5 mg; Prednisone 5 mg tablets; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and belimumab; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, ciclosporin and mycophenolate mofetil; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, low dose rituximab; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Procedure: thymectomy plus prednisone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Ursodeoxycholic acid+low dose glucocorticoid(prednisone); | 1件: D00473 D00473 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
29 | Ruxolitinib | Ruxolitinib 1件: Ruxolitinib; | 1件: D09959 D09959 💬 |
2件: JAK1, JAK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 33件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
228 1件: 228 💬 |
30 | Salbutamol | Nebulized combination ipratropium bromide with salbutamol 9件: Nebulized combination ipratropium bromide with salbutamol; Other: salbutamol nebulisation and with cpap; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet; Salbutamol sulfate; Salbutamol sulfate ph. eur.; Salbutamol wzf 4 mg; | 1件: D02147 D02147 💬 |
1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
003 14件: 3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬 |
31 | Sodium chloride | 0.9% sodium chloride 24件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v isotonic sodium chloride solution; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Other: 0.9% sodium chloride; Other: 0.9ml sodium chloride; Other: sodium chloride; Physiological serum (sodium chloride); Procedure: 9% sodium chloride (nacl) iv; Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 0.9%; Sodium chloride 6%; Sodium chloride 7%; Sodium chloride ph. eur.; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; Solucion de cloruro de sodio sodium chloride solution; Solvente cloruro de sodio sodium chloride solvent; | 1件: D02056 D02056 💬 |
- |
- |
006 20件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
32 | Tacrolimus | Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf 17件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Rectal tacrolimus; Symptomatic treatment, steroids, immunosuppressive agents( azathioprine, tacrolimus, mycophenolate mofetil); Tacrolimus; Tacrolimus (advagraf); Tacrolimus (prograf®); Tacrolimus (tacro); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsule (low-dose); Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus tablets; Tacrolimus with methotrexate; | 2件: D00107 D00107
D08556 D08556 💬 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 32件: 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
33 | Vitamin D | 10000iu vitamin d 36件: 10000iu vitamin d; 19 nor vitamin d; 25-hydroxyvitamin d3; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Calcium and vitamin d combination; Cholecalciferol (vitamin d3); Cholecalciferol, vitamin d3; D6-25-hydroxyvitamin d3; Diagnostic test: vitamin d measurement; Ergocalciferol (vitamin d2); High-dose vitamin d (2000 iu per day); High-dose vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Other: baseline serum vitamin d level at or above 50 nmol/l; Other: baseline serum vitamin d level below 50 nmol/l; Standard-dose vitamin d (400iu per day); Supplementation with vitamin d2/d3; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d drops; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; Vitamin d2; Vitamin d3; Vitamin d3 3000 ui daily; Vitamin d3 400 iu; Vitamin d3 4000 ui daily; Vitamin d3 6000 iu; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; | - |
- |
- |
013 21件: 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 274, 298, 299 💬 |
34 | Xenon | Hp 129xenon 12件: Hp 129xenon; Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment; Hyperpolarized 129-xenon gas; Hyperpolarized xenon; Hyperpolarized xenon 129; Hyperpolarized xenon gas; Hyperpolarized xenon-129; Other: hyperpolarized xenon mri; Other: inhaled hyperpolarized xenon-129; Xenon; Xenon contrast agent; Xenon-129; | 2件: D01901 D01901
D06339 D06339 💬 |
- |
- |
022 4件: 22, 85, 228, 299 💬 |